Evolus Inc (EOLS)

$8.31 +0.13 (1.59%)
Market Cap 513.21M
Revenue (ttm) 297.18M
Net Income (ttm) -51.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17.38%
Debt to Equity Ratio -5.07
Volume 243,734
Avg Vol 869,748
Day's Range N/A - N/A
Shares Out 66.05M
Stochastic %K 87%
Beta 1.35
Analysts Strong Sell
Price Target $15.60

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
Doozio
Doozio Aug. 18 at 7:23 PM
$EOLS feels like it’s gonna get NUTX
0 · Reply
kgnfdeagle
kgnfdeagle Aug. 14 at 8:53 PM
$EOLS Started a 500 share position at $8.15; this is primed to run.
0 · Reply
Doozio
Doozio Aug. 12 at 12:43 AM
$EOLS dips appear a 🎁
0 · Reply
Doozio
Doozio Aug. 7 at 3:29 AM
$EOLS it can’t be a Thursday 🐑 if it’s ….🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Aug. 6 at 11:35 PM
$EOLS 🐒🍌🧠⏰♾️
0 · Reply
PaulBismuthFr
PaulBismuthFr Aug. 6 at 3:40 PM
$EOLS The situation today :)
0 · Reply
Doozio
Doozio Aug. 6 at 2:07 AM
$EOLS chop chop huckleberries n eps gap n goes ………
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 8:23 PM
$EOLS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 up 55.56% YoY • Reported revenue of $84.08M up 21.18% YoY • Evolus raised full-year 2026 net revenue guidance to between $330 million and $337 million, adjusted gross profit margin to between 67.0% and 67.5%, and narrowed non-GAAP operating expense guidance to $212-$216 million.
0 · Reply
Estimize
Estimize Aug. 5 at 3:01 PM
$EOLS reports after the close, Estimize Consensus -0 EPS and +0.68M Revs compared to WS http://www.estimize.com/eols/fq2-2026?utm_content=p
0 · Reply
rahmanoof
rahmanoof Jul. 27 at 5:39 PM
$EOLS earning season is near
0 · Reply
Latest News on EOLS
Evolus reports Q2 EPS (12c), consensus (4c)

2026-08-05T20:45:55.000Z - 13 days ago

Evolus reports Q2 EPS (12c), consensus (4c)

Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M

2026-08-05T20:45:44.000Z - 13 days ago

Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M

Evolus Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Evolus Earnings Call Transcript: Q2 2026

Evolus Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Evolus Earnings release: Q2 2026

Evolus Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Evolus Slides: Q2 2026

Evolus Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Evolus Quarterly report: Q2 2026

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus expands strategic partnership with Symatese to commercialize Estyme

2026-08-04T12:35:44.000Z - 15 days ago

Evolus expands strategic partnership with Symatese to commercialize Estyme

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Aug 4, 2026, 8:30 AM EDT - 15 days ago

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus Slides: Scientific Investor presentation

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Evolus Slides: Scientific Investor presentation

Evolus to Report Second Quarter Financial Results on August 5, 2026

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2026, 4:05 PM EDT - 5 weeks ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus partners with IBSA to develop and market Profhilo in the U.S.

2026-07-08T13:10:28.000Z - 6 weeks ago

Evolus partners with IBSA to develop and market Profhilo in the U.S.

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Jul 8, 2026, 9:00 AM EDT - 6 weeks ago

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Evolus Transcript: AGM 2026

Jun 11, 2026, 11:00 AM EDT - 2 months ago

Evolus Transcript: AGM 2026

Evolus files $250M mixed securities shelf

2026-06-05T20:50:42.000Z - 2 months ago

Evolus files $250M mixed securities shelf

Evolus Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Evolus Registration statement: Registration filing

Evolus management to meet virtually with BTIG

2026-06-04T19:10:13.000Z - 2 months ago

Evolus management to meet virtually with BTIG

Evolus Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Evolus Transcript: Jefferies Global Healthcare Conference 2026

Evolus to Participate in The Jefferies Global Healthcare Conference

May 19, 2026, 8:30 AM EDT - 3 months ago

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus announces commercial launch of Estyme in Europe

2026-05-11T15:19:15.000Z - 3 months ago

Evolus announces commercial launch of Estyme in Europe

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

May 11, 2026, 8:30 AM EDT - 3 months ago

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Evolus Earnings Call Transcript: Q1 2026

Evolus Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Evolus Earnings release: Q1 2026

Evolus Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Evolus Slides: Q1 2026

Evolus Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Evolus Quarterly report: Q1 2026

Evolus reports Q1 EPS (16c), consensus (12c)

2026-05-04T20:13:04.000Z - 3 months ago

Evolus reports Q1 EPS (16c), consensus (12c)

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

May 4, 2026, 4:05 PM EDT - 3 months ago

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Weight-loss revolution sparks new appetite for aesthetics firms

May 4, 2026, 11:16 AM EDT - 3 months ago

Weight-loss revolution sparks new appetite for aesthetics firms

APYX ESTA INMD

Evolus Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 3 months ago

Evolus Slides: Investor presentation

Evolus Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Evolus Proxy statement: Proxy filing

Evolus Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Evolus Proxy statement: Proxy filing

Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 3:45 PM EDT - 4 months ago

Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference

Evolus to Report First Quarter Financial Results on May 4, 2026

Apr 14, 2026, 8:30 AM EDT - 4 months ago

Evolus to Report First Quarter Financial Results on May 4, 2026

Evolus Slides: Investor presentation

Apr 10, 2026, 7:00 AM EDT - 4 months ago

Evolus Slides: Investor presentation

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 11:20 AM EDT - 5 months ago

Evolus Transcript: Leerink Global Healthcare Conference 2026

Evolus Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Evolus Earnings Call Transcript: Q4 2025

Evolus Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Evolus Annual report: Q4 2025

Evolus Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Evolus Earnings release: Q4 2025

Evolus Slides: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Evolus Slides: Q4 2025

Evolus sees FY26 revenue $327M-$337M, consensus $329.66M

2026-03-03T21:21:20.000Z - 6 months ago

Evolus sees FY26 revenue $327M-$337M, consensus $329.66M

Evolus reports Q4 EPS 0c, consensus 4c

2026-03-03T21:10:39.000Z - 6 months ago

Evolus reports Q4 EPS 0c, consensus 4c

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Mar 3, 2026, 4:05 PM EST - 6 months ago

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Feb 17, 2026, 8:00 AM EST - 6 months ago

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Evolus price target lowered to $15 from $19 at Mizuho

2026-02-04T12:36:31.000Z - 7 months ago

Evolus price target lowered to $15 from $19 at Mizuho

Evolus price target lowered to $13 from $18 at BTIG

2026-01-22T12:21:40.000Z - 7 months ago

Evolus price target lowered to $13 from $18 at BTIG

Evolus price target lowered to $17 from $20 at Stifel

2026-01-13T12:16:01.000Z - 7 months ago

Evolus price target lowered to $17 from $20 at Stifel

Evolus narrows FY25 revenue view to $295.5M-$297.5M from $295M-$305M

2026-01-09T13:52:35.000Z - 7 months ago

Evolus narrows FY25 revenue view to $295.5M-$297.5M from $295M-$305M

Evolus sees FY26 revenue $327M-$337M, consensus $351.66M

2026-01-09T13:52:00.000Z - 7 months ago

Evolus sees FY26 revenue $327M-$337M, consensus $351.66M

Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M

2026-01-09T13:45:31.000Z - 7 months ago

Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Jan 9, 2026, 8:30 AM EST - 7 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Evolus price target lowered to $19 from $20 at Mizuho

2025-12-02T12:15:41.000Z - 9 months ago

Evolus price target lowered to $19 from $20 at Mizuho

Evolus Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 11:20 AM EST - 10 months ago

Evolus Transcript: Stifel 2025 Healthcare Conference

Evolus Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Evolus Earnings Call Transcript: Q3 2025

Evolus Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Evolus Quarterly report: Q3 2025

Evolus Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Evolus Earnings release: Q3 2025

Evolus Slides: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Evolus Slides: Q3 2025

Evolus Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 10 months ago

Evolus Reports Third Quarter 2025 Financial Results

Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus to Report Third Quarter Financial Results on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Evolus to Report Third Quarter Financial Results on November 5, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Sep 22, 2025, 9:03 AM EDT - 11 months ago

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2025, 5:30 PM EDT - 1 year ago

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 20, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Evolus Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Evolus Earnings Call Transcript: Q2 2025

Evolus Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Evolus Quarterly report: Q2 2025

Evolus Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Evolus Earnings release: Q2 2025

Evolus Slides: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Evolus Slides: Q2 2025

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Evolus Slides: Investor Presentation

Aug 4, 2025, 6:00 PM EDT - 1 year ago

Evolus Slides: Investor Presentation

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 31, 2025, 8:05 AM EDT - 1 year ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 22, 2025, 8:05 AM EDT - 1 year ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Evolysse™ Recognized in 2025 Shape Skin Awards

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 1 year ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Slides: Investor Presentation

May 15, 2025, 7:00 AM EDT - 1 year ago

Evolus Slides: Investor Presentation

Evolus Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Evolus Earnings Call Transcript: Q1 2025

Evolus Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Evolus Quarterly report: Q1 2025

Evolus Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Evolus Earnings release: Q1 2025

Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 5, 2025, 4:05 PM EDT - 1 year ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Evolus Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Evolus Proxy statement: Proxy Filing

Evolus Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Evolus Proxy statement: Proxy Filing

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 12:45 PM EDT - 1 year ago

Evolus Transcript: 24th Annual Needham Virtual Healthcare Conference

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 3:30 PM EDT - 1 year ago

Evolus Transcript: Barclays 27th Annual Global Healthcare Conference

Evolus Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 9:20 AM EDT - 1 year ago

Evolus Transcript: Leerink’s Global Healthcare Conference 2025

Evolus Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Evolus Earnings Call Transcript: Q4 2024

Evolus Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Evolus Annual report: Q4 2024

Evolus Earnings release: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Evolus Earnings release: Q4 2024

Evolus Slides: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Evolus Slides: Q4 2024

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:17 PM EST - 1 year ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Mar 4, 2025, 4:05 PM EST - 1 year ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 27, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 20, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 1 year ago

US FDA approves Evolus' anti-wrinkle gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Feb 13, 2025, 1:30 PM EST - 1 year ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 21, 2025, 8:00 AM EST - 1 year ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus Slides: Investor Presentation

Jan 21, 2025, 7:00 AM EST - 1 year ago

Evolus Slides: Investor Presentation

Evolus Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Evolus Transcript: Stifel 2024 Healthcare Conference

Evolus Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Evolus Earnings Call Transcript: Q3 2024

Evolus Quarterly report: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Evolus Quarterly report: Q3 2024

Evolus Earnings release: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Evolus Earnings release: Q3 2024

Evolus Slides: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Evolus Slides: Q3 2024

Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 31, 2024, 2:02 PM EDT - 1 year ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Transcript: Investor Day 2024

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Evolus Transcript: Investor Day 2024

Evolus Slides: FY 2024

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Evolus Slides: FY 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Sep 6, 2024, 8:00 AM EDT - 2 years ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Doozio
Doozio Aug. 18 at 7:23 PM
$EOLS feels like it’s gonna get NUTX
0 · Reply
kgnfdeagle
kgnfdeagle Aug. 14 at 8:53 PM
$EOLS Started a 500 share position at $8.15; this is primed to run.
0 · Reply
Doozio
Doozio Aug. 12 at 12:43 AM
$EOLS dips appear a 🎁
0 · Reply
Doozio
Doozio Aug. 7 at 3:29 AM
$EOLS it can’t be a Thursday 🐑 if it’s ….🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Aug. 6 at 11:35 PM
$EOLS 🐒🍌🧠⏰♾️
0 · Reply
PaulBismuthFr
PaulBismuthFr Aug. 6 at 3:40 PM
$EOLS The situation today :)
0 · Reply
Doozio
Doozio Aug. 6 at 2:07 AM
$EOLS chop chop huckleberries n eps gap n goes ………
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 8:23 PM
$EOLS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 up 55.56% YoY • Reported revenue of $84.08M up 21.18% YoY • Evolus raised full-year 2026 net revenue guidance to between $330 million and $337 million, adjusted gross profit margin to between 67.0% and 67.5%, and narrowed non-GAAP operating expense guidance to $212-$216 million.
0 · Reply
Estimize
Estimize Aug. 5 at 3:01 PM
$EOLS reports after the close, Estimize Consensus -0 EPS and +0.68M Revs compared to WS http://www.estimize.com/eols/fq2-2026?utm_content=p
0 · Reply
rahmanoof
rahmanoof Jul. 27 at 5:39 PM
$EOLS earning season is near
0 · Reply
lknite
lknite Jul. 22 at 7:45 PM
$EOLS a slower moving stock ...
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Jul. 9 at 6:45 PM
$AIRS $APYX $EOLS
0 · Reply
focafoca99
focafoca99 Jul. 8 at 1:18 PM
$EOLS struck a license agreement with IBSA to commercialize Profhilo in the U.S.
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Jun. 24 at 4:53 PM
$APYX $EOLS $AIRS Should be a fun summer w three tickers w bullseyes on em - the rotation should be fun
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 10:13 AM
$EOLS Share Price: $6.18 Contract Selected: Jan 15, 2027 $5 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.86 – $3.49 Potential Upside: 76% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
goofyfoot
goofyfoot May. 23 at 9:29 PM
$EOLS What caused this to drop so much on Friday?
0 · Reply
focafoca99
focafoca99 May. 22 at 2:47 PM
$EOLS began its European launch of Estyme and wrapped up a key NUCEIVA safety study.
0 · Reply
d_risk
d_risk May. 5 at 3:47 PM
$EOLS - Evolus Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +78.0% above peer average (21,403 vs 12,026 across 652 peers). Evolus’ 10-Q flags mounting pressure on a loss-making, cash-pay aesthetics model: intensified neurotoxin/HA competition vs AbbVie/Galderma, new macro/tariff and Medytox royalty headwinds, heavy reliance on sole foreign licensors and digital/AI systems, expanded global regulatory/IP and data/privacy risk, plus heightened talent, financing, governance and stock-volatility concerns. 🟢 Added 🟠 Removed https://d-risk.ai/EOLS/10-Q/2026-05-04
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 5 at 2:30 PM
$EOLS is great for the space and great for $AIRS - the space is a coming back..
0 · Reply
Finitemaf
Finitemaf May. 4 at 10:09 PM
$EOLS
0 · Reply
HellenJune
HellenJune May. 4 at 9:24 PM
$EOLS What's the deal?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 4 at 8:13 PM
$EOLS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 46.67% YoY • Reported revenue of $73.14M up 6.74% YoY • Evolus reaffirms full-year 2026 net revenue guidance of $327M to $337M and non-GAAP operating expenses of $210M to $216M, expecting a low- to mid-single digit Adjusted EBITDA margin.
0 · Reply